LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 66

Search options

  1. Article ; Online: Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward.

    Bhoori, Sherrie / Mazzaferro, Vincenzo

    The Lancet. Oncology

    2020  Volume 21, Issue 6, Page(s) 740–741

    MeSH term(s) Antibodies, Monoclonal, Humanized ; Bevacizumab ; Carcinoma, Hepatocellular ; Humans ; Immunotherapy ; Liver Neoplasms ; Vascular Endothelial Growth Factor A
    Chemical Substances Antibodies, Monoclonal, Humanized ; Vascular Endothelial Growth Factor A ; Bevacizumab (2S9ZZM9Q9V) ; atezolizumab (52CMI0WC3Y)
    Language English
    Publishing date 2020-06-04
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(20)30211-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Hepatocellular Carcinoma Recurrence After Liver Transplantation.

    Gabutti, Alejandro / Bhoori, Sherrie / Cascella, Tommaso / Bongini, Marco

    Oncology (Williston Park, N.Y.)

    2020  Volume 34, Issue 3

    Abstract: Key Points • Recurrent HCC after OLT management is challenging and notoriously difficult. • High oncologic-risk patient identification and close follow-up are essential. • Recurrences diagnosed within the first 2 years after OLT can be classified as ... ...

    Abstract Key Points • Recurrent HCC after OLT management is challenging and notoriously difficult. • High oncologic-risk patient identification and close follow-up are essential. • Recurrences diagnosed within the first 2 years after OLT can be classified as early-onset and are associated with poor prognosis. • Surgical resection should be the first curative attempt when it is technically feasible. • TACE in patients who have undergone OLT appears to be effective and safe. • Sorafenib can be used as systemic therapy in cases with multi-organ recurrence; newer therapies are emerging. • The benefit of immunosuppression with an mTOR inhibitor has not been established. • In the posttransplant setting, a combination treatment approach is warranted.
    MeSH term(s) Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/surgery ; Combined Modality Therapy ; Female ; Hepatitis C/pathology ; Humans ; Liver Neoplasms/etiology ; Liver Neoplasms/pathology ; Liver Neoplasms/surgery ; Liver Transplantation ; Middle Aged ; Neoplasm Recurrence, Local/etiology ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Risk Factors ; Treatment Outcome
    Language English
    Publishing date 2020-03-19
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1067950-9
    ISSN 0890-9091
    ISSN 0890-9091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues.

    Maspero, Marianna / Sposito, Carlo / Virdis, Matteo / Citterio, Davide / Pietrantonio, Filippo / Bhoori, Sherrie / Belli, Filiberto / Mazzaferro, Vincenzo

    Cancers

    2023  Volume 15, Issue 2

    Abstract: More than 40% of patients with colorectal cancer present liver metastases (CRLM) during the course of their disease and up to 50% present with unresectable disease. Without surgical interventions, survival for patients treated with systemic therapies ... ...

    Abstract More than 40% of patients with colorectal cancer present liver metastases (CRLM) during the course of their disease and up to 50% present with unresectable disease. Without surgical interventions, survival for patients treated with systemic therapies alone is dismal. In the past, liver transplantation (LT) for patients with unresectable CRLM failed to show any survival benefit due to poor selection, ineffective chemotherapeutic regimens, unbalanced immunosuppression and high perioperative mortality. Since then and for many years LT for CRLM was abandoned. The turning point occurred in 2013, when the results from the Secondary Cancer (SECA I) pilot study performed at Oslo University were published reporting a 60% 5-year overall survival after LT in patients with unresectable CRLM. These results effectively reignited the interest in LT as a potential therapy for CRLM, and several trials are undergoing. The aims of this article are to give a comprehensive overview of the available evidence on LT for CRLM, discuss the open issues in this rapidly evolving field, and highlight possible ways to address the future of this fascinating therapeutic alternative for selected patients with CRLM.
    Language English
    Publishing date 2023-01-05
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15020345
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy.

    Bhoori, Sherrie / Rossi, Roberta Elisa / Citterio, Davide / Mazzaferro, Vincenzo

    The lancet. Gastroenterology & hepatology

    2020  Volume 5, Issue 6, Page(s) 532–533

    MeSH term(s) Aged ; Betacoronavirus/isolation & purification ; COVID-19 ; Coronavirus Infections/mortality ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Italy/epidemiology ; Liver Transplantation/adverse effects ; Liver Transplantation/mortality ; Male ; Pandemics ; Pneumonia, Viral/mortality ; SARS-CoV-2 ; Transplant Recipients/statistics & numerical data
    Chemical Substances Immunosuppressive Agents
    Keywords covid19
    Language English
    Publishing date 2020-04-09
    Publishing country Netherlands
    Document type Letter
    ISSN 2468-1253
    ISSN (online) 2468-1253
    DOI 10.1016/S2468-1253(20)30116-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better.

    Mazzaferro, Vincenzo / Droz Dit Busset, Michele / Bhoori, Sherrie

    Hepatology (Baltimore, Md.)

    2018  Volume 68, Issue 2, Page(s) 775–777

    MeSH term(s) Carcinoma, Hepatocellular ; Humans ; Liver Cirrhosis ; Liver Neoplasms ; Liver Transplantation ; alpha-Fetoproteins
    Chemical Substances alpha-Fetoproteins
    Language English
    Publishing date 2018-05-14
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 604603-4
    ISSN 1527-3350 ; 0270-9139
    ISSN (online) 1527-3350
    ISSN 0270-9139
    DOI 10.1002/hep.29835
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Y

    Rivoltini, Licia / Bhoori, Sherrie / Camisaschi, Chiara / Bergamaschi, Laura / Lalli, Luca / Frati, Paola / Citterio, Davide / Castelli, Chiara / Mazzaferro, Vincenzo

    Gut

    2022  Volume 72, Issue 2, Page(s) 406–407

    MeSH term(s) Humans ; Carcinoma, Hepatocellular/radiotherapy ; Liver Neoplasms/radiotherapy ; Embolization, Therapeutic ; Immunotherapy
    Language English
    Publishing date 2022-05-04
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 80128-8
    ISSN 1468-3288 ; 0017-5749
    ISSN (online) 1468-3288
    ISSN 0017-5749
    DOI 10.1136/gutjnl-2021-326869
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Current challenges in liver transplantation for hepatocellular carcinoma.

    Bhoori, Sherrie / Mazzaferro, Vincenzo

    Best practice & research. Clinical gastroenterology

    2014  Volume 28, Issue 5, Page(s) 867–879

    Abstract: Liver transplantation (LT) is the best option of cure for hepatocellular carcinoma (HCC). Notwithstanding several alternatives, Milan Criteria remain the cornerstone for patient selection. Currently, expanded criteria patients are unsuitable for LT ... ...

    Abstract Liver transplantation (LT) is the best option of cure for hepatocellular carcinoma (HCC). Notwithstanding several alternatives, Milan Criteria remain the cornerstone for patient selection. Currently, expanded criteria patients are unsuitable for LT without taking downstaging approaches and response to therapies into consideration. Relative weight of HCC as indication to LT is increasing and that generates competition with MELD-described non-cancer indications. Allocation policies should be adjusted accordingly, considering principles of urgency and utility in the management of the waiting list and including transplant benefit to craft equitable criteria to deal with the limited resource of donated grafts. Maximization of cost-effectiveness of LT in HCC can be also pursued through changes in immunosuppression policies and multimodal management of post-transplant recurrences. This review is focused on those constantly mutating challenges that have to be faced by anyone dealing with the management of HCC in the context of liver transplantation.
    MeSH term(s) Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/surgery ; Humans ; Liver Neoplasms/pathology ; Liver Neoplasms/surgery ; Liver Transplantation ; Patient Selection ; Resource Allocation ; Waiting Lists
    Language English
    Publishing date 2014-10
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2048181-0
    ISSN 1532-1916 ; 1521-6918
    ISSN (online) 1532-1916
    ISSN 1521-6918
    DOI 10.1016/j.bpg.2014.08.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma.

    Claasen, Marco Petrus Adrianus Wilhelmus / Sneiders, Dimitri / Rakké, Yannick Sebastiaan / Adam, René / Bhoori, Sherrie / Cillo, Umberto / Fondevila, Constantino / Reig, Maria / Sapisochin, Gonzalo / Tabrizian, Parissa / Toso, Christian

    Transplant international : official journal of the European Society for Organ Transplantation

    2023  Volume 36, Page(s) 11648

    Abstract: Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional ... ...

    Abstract Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional treatments such as ablation and transarterial chemoembolization. These aforementioned treatments are being applied as bridging therapies to keep patients within transplant criteria and to avoid them from dropping out of the waiting list while awaiting a liver transplant. Moreover, immunotherapy might have great potential to support downstaging and bridging therapies. To address the contemporary status of downstaging, bridging, and immunotherapy in liver transplantation for HCC, European Society of Organ Transplantation (ESOT) convened a dedicated working group comprised of experts in the treatment of HCC to review literature and to develop guidelines pertaining to this cause that were subsequently discussed and voted during the Transplant Learning Journey (TLJ) 3.0 Consensus Conference that took place in person in Prague. The findings and recommendations of the working group on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma are presented in this article.
    MeSH term(s) Humans ; Carcinoma, Hepatocellular/surgery ; Carcinoma, Hepatocellular/pathology ; Liver Neoplasms/surgery ; Liver Neoplasms/pathology ; Liver Transplantation/adverse effects ; Treatment Outcome ; Chemoembolization, Therapeutic/adverse effects ; Neoadjuvant Therapy/adverse effects ; Neoplasm Staging ; Immunotherapy
    Language English
    Publishing date 2023-09-14
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 639435-8
    ISSN 1432-2277 ; 0934-0874
    ISSN (online) 1432-2277
    ISSN 0934-0874
    DOI 10.3389/ti.2023.11648
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors.

    Sposito, Carlo / Rossi, Roberta Elisa / Monteleone, Michela / Coppa, Jorgelina / Bongini, Marco / Milione, Massimo / Bhoori, Sherrie / Mazzaferro, Vincenzo

    Transplantation

    2021  Volume 105, Issue 12, Page(s) 2579–2586

    Abstract: Background: Liver metastases from neuroendocrine tumors (NETs) are an accepted indication for liver transplantation (LT). Despite strict patient selection, post-LT recurrence is observed in 30%-50% of cases. Postrecurrence survival is poorly ... ...

    Abstract Background: Liver metastases from neuroendocrine tumors (NETs) are an accepted indication for liver transplantation (LT). Despite strict patient selection, post-LT recurrence is observed in 30%-50% of cases. Postrecurrence survival is poorly investigated as well as factors influencing postrecurrence outcomes.
    Methods: Consecutive patients treated at a single institution for post-LT recurrence of NET between January 1, 2004, and December 31, 2018, were included. Baseline patients' characteristics, data on the primary tumor, pretransplant therapies, posttransplant recurrence and treatments, and long-term outcomes were prospectively collected and retrospectively analyzed.
    Results: Thirty-two patients presented with post-LT NET recurrence occurring 82.9 mo (interquartile range, 29.4-119.1 mo) from LT, and the most common sites were abdominal lymph nodes (59.4%), peritoneum (6.3%), and lungs (6.3%). Fourteen patients (43.8%) underwent surgery with radical intent. Five- and 10-y survival after recurrence were 76.3% and 45.5%, respectively. Only time from LT to recurrence had a significant impact on postrecurrence survival, being 5-y overall survival 89.5% versus 0% for patients recurring >24 mo after LT versus ≤24 mo, respectively (P = 0.001). Moreover, for patients with Ki-67 monoclonal antibody staining >2% at recurrence, 5 y overall survival was 87.5% versus 0% for those undergoing surgery versus locoregional or systemic treatments (P = 0.011).
    Conclusions: The presented results, although based on a retrospective and relatively small series, show that excellent long-term survival is observed after post-LT NET recurrence, particularly in those patients recurring long after LT (>24 mo). An aggressive surgical treatment might result in a new chance of cure for a selected subgroup of patients.
    MeSH term(s) Carcinoma, Hepatocellular ; Humans ; Liver Neoplasms ; Liver Transplantation/adverse effects ; Neoplasm Recurrence, Local/etiology ; Neuroendocrine Tumors/surgery ; Retrospective Studies ; Treatment Outcome
    Language English
    Publishing date 2021-04-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000003802
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.

    Spada, Francesca / Rossi, Roberta E / Kara, Elda / Laffi, Alice / Massironi, Sara / Rubino, Manila / Grimaldi, Franco / Bhoori, Sherrie / Fazio, Nicola

    Pharmaceuticals (Basel, Switzerland)

    2021  Volume 14, Issue 6

    Abstract: The carcinoid syndrome (CS) and hyperinsulinemic hypoglycemia (HH) represent two of the most common clinical syndromes associated with neuroendocrine neoplasms (NENs). The former is mainly related to the serotonin secretion by a small bowel NEN, whereas ... ...

    Abstract The carcinoid syndrome (CS) and hyperinsulinemic hypoglycemia (HH) represent two of the most common clinical syndromes associated with neuroendocrine neoplasms (NENs). The former is mainly related to the serotonin secretion by a small bowel NEN, whereas the latter depends on an insulin hypersecretion by a pancreatic insulinoma. Both syndromes/conditions can affect prognosis and quality of life of patients with NENs. They are often diagnosed late when patients become strongly symptomatic. Therefore, their early detection and management are a critical step in the clinical management of NEN patients. A dedicated and experienced multidisciplinary team with appropriate therapeutic strategies is needed and should be encouraged to optimize clinical outcomes. This review aims to critically analyze clinical features, evidence and treatment options of CS and HH and therefore to improve their management.
    Language English
    Publishing date 2021-06-04
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph14060539
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top